Tech Company Financing Transactions
Biosyntia Funding Round
Biosyntia, based in Copenhagen, secured $11.7 million from ECBF - European Circular Bioeconomy Fund, Novo Holdings and Sofinnova Partners.
Transaction Overview
Company Name
Announced On
7/7/2022
Transaction Type
Venture Equity
Amount
$11,700,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to enter the production phase of its natural and sustainable active ingredients as well as expand the pipeline of products.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Fruebjergvej 3, boks 54
Copenhagen, DK-2100
Denmark
Copenhagen, DK-2100
Denmark
Phone
Undisclosed
Website
Email Address
Overview
The world population is expected to grow to 9.7 billion by 2050. Most dietary ingredients critical for a healthy population are today sourced from either crop- or animal extraction or petrochemical synthesis. Our approach will fundamentally change how ingredients are produced and ensure that we can affordably supply nature's ingredients without the need for increasing cropland or animal production. And without the use of petrochemistry.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Martin Plambech
Chief Scientific Officer
Hans Genee
Chief Technical Officer
Jochen Förster
Browse more venture capital transactions:
Prev: 7/7/2022: Zhiyi Biotech venture capital transaction
Next: 7/7/2022: Hidden Road Partners venture capital transaction
Share this article
News on VC Transactions
We report on all VC transactions involving tech companies. VC investment data records on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs